Top Page
New China Life Insurance Co., Ltd. Class H
(1336)
New China Life Insurance Co., Ltd. Class H (1336) vs. iShares MSCI Hong Kong ETF (EWH)
New China Life Insurance Co., Ltd. Class H Business Overview & Revenue Model
New China Life Insurance Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 116.92B | 128.86B | 70.10B | 106.89B | 222.00B | 206.28B |
| Gross Profit | 116.92B | 128.86B | 70.10B | 96.72B | 207.41B | 188.45B |
| EBITDA | 61.28B | 29.88B | 67.84B | 99.86B | 17.29B | 17.01B |
| Net Income | 29.95B | 26.23B | 8.71B | 21.50B | 14.95B | 14.29B |
Balance Sheet | ||||||
| Total Assets | 1.78T | 1.69T | 1.40T | 1.26T | 1.13T | 1.00T |
| Cash, Cash Equivalents and Short-Term Investments | 32.58B | 38.46B | 21.81B | 393.24B | 418.90B | 439.70B |
| Total Debt | 20.91B | 31.10B | 21.02B | 10.86B | 11.04B | 11.06B |
| Total Liabilities | 1.69T | 1.60T | 1.30T | 1.15T | 1.02T | 902.70B |
| Stockholders Equity | 83.41B | 96.24B | 105.07B | 102.88B | 108.50B | 101.67B |
Cash Flow | ||||||
| Free Cash Flow | 65.44B | 95.19B | 89.46B | 87.60B | 70.59B | 64.14B |
| Operating Cash Flow | 58.72B | 96.29B | 91.55B | 89.39B | 73.85B | 67.18B |
| Investing Cash Flow | -131.48B | -141.77B | -156.65B | -90.47B | -106.53B | -67.73B |
| Financing Cash Flow | 44.14B | 62.03B | 69.29B | 2.84B | 35.24B | 1.97B |
New China Life Insurance Co., Ltd. Class H Technical Analysis
New China Life Insurance Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | HK$202.54B | 4.72 | 34.37% | 5.94% | 49.90% | 203.77% | |
83 Outperform | $1.17T | 5.89 | 28.10% | 3.72% | 17.69% | 126.41% | |
76 Outperform | $352.34B | 5.36 | 18.41% | 3.65% | 15.08% | 23.13% | |
72 Outperform | $1.10T | 6.75 | 14.53% | 4.82% | 10.20% | 19.74% | |
72 Outperform | $862.52B | 18.85 | 15.16% | 2.21% | 5.65% | 30.47% | |
71 Outperform | €67.12B | 5.62 | 11.12% | 3.34% | 2.54% | 17.80% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
New China Life Insurance Co., Ltd. Class H Corporate Events
New China Life Insurance Co., Ltd. reported an accumulated gross premium income of RMB181,973.02 million for the period from January to October 2025, marking a 17% increase year-on-year. The company is committed to high-quality development through systematic reforms and efforts across various dimensions, including products, distribution channels, and technology, aiming for both volume and value enhancement.
The most recent analyst rating on (HK:1336) stock is a Sell with a HK$37.90 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. announced an update to its interim dividend for the six months ending June 30, 2025, declaring a dividend of RMB 0.67 per share. The update includes details on the default currency, exchange rate, and withholding tax for the dividend, which will be paid in HKD. The ex-dividend date is set for November 13, 2025, with payment scheduled for December 12, 2025. The announcement outlines the withholding tax rates applicable to non-resident shareholders based on their domicile’s tax treaty with China, impacting the net dividend received by these stakeholders.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$65.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. recently held its third extraordinary general meeting of 2025, where shareholders approved the Interim Profit Distribution Plan for the year. The meeting, which complied with relevant legal and regulatory requirements, saw significant shareholder participation, with a resolution passed to distribute interim dividends, reflecting the company’s commitment to returning value to its shareholders.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$65.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. reported its unaudited financial results for the third quarter of 2025, showcasing a substantial increase in both operating income and net profit. The company achieved a 30.8% rise in operating income and an 88.2% surge in net profit attributable to shareholders for the three months ended September 30, 2025, compared to the same period last year. These results highlight the company’s strong financial performance and improved profitability, which could positively impact its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$65.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. has announced that its board of directors will hold a meeting on October 30, 2025, to review and approve the company’s third-quarter results for the nine months ending September 30, 2025. This meeting is crucial as it will also involve the publication of these results, which could impact the company’s operational strategies and provide insights into its financial health for stakeholders.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$65.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. reported an accumulated gross premium income of RMB172,704.62 million for the first nine months of 2025, marking a 19% increase year-on-year. The company is enhancing its business structure by transitioning to participating insurance, upgrading its ‘Strong Foundation Initiative,’ and strengthening its sales and distribution channels to support high-quality development.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$65.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. has announced a significant estimated profit increase for the first three quarters of 2025, with net profit expected to grow by 45% to 65% compared to the same period in 2024. This growth is attributed to the company’s strategic focus on enhancing its insurance business quality, optimizing asset allocation, and leveraging the strong performance of China’s capital market, leading to substantial investment returns.
The most recent analyst rating on (HK:1336) stock is a Sell with a HK$37.90 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. has announced the convening of its third extraordinary general meeting of 2025, scheduled for October 31, 2025. Key agenda items include the approval of an interim profit distribution plan, amendments to the Articles of Association, and changes to the rules of procedures for both the general meeting and the board of directors. The outcomes of these resolutions could significantly impact the company’s governance structure and shareholder engagement, reflecting its strategic direction and operational priorities.
The most recent analyst rating on (HK:1336) stock is a Sell with a HK$37.90 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. has announced an update to its interim cash dividend for the six months ending June 30, 2025, declaring a dividend of RMB 0.67 per share. The announcement includes updated details on the shareholders’ approval date, ex-dividend rate, and other key dates, impacting stakeholders by providing clarity on dividend entitlements and payment schedules.
The most recent analyst rating on (HK:1336) stock is a Sell with a HK$37.90 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. announced proposed amendments to its Articles of Association and the abolishment of its Board of Supervisors. This move aims to align with the Company Law of China and improve corporate governance. The changes are subject to approval at the shareholders’ general meeting and will take effect upon approval by the National Financial Regulatory Administration. The dissolution of the Board of Supervisors is expected to streamline operations and enhance governance practices.
The most recent analyst rating on (HK:1336) stock is a Sell with a HK$37.90 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. reported an accumulated gross premium income of RMB158,085.85 million for the first eight months of 2025, marking a 21% year-on-year increase. The company is focused on strengthening its market position by enhancing its operational capabilities and management efforts, aiming for high-quality development and structural optimization.
The most recent analyst rating on (HK:1336) stock is a Hold with a HK$50.70 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. has announced an interim cash dividend of RMB 0.67 per share for the six months ending June 30, 2025. This announcement reflects the company’s financial performance and commitment to providing returns to its shareholders, although specific details such as the Hong Kong dollar equivalent, ex-dividend date, and payment date are yet to be announced.
The most recent analyst rating on (HK:1336) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. has released supplementary information regarding the remuneration of its directors, supervisors, and senior management for 2023. The announcement includes final total remuneration figures for various executives, highlighting changes in positions and responsibilities within the company. This disclosure provides transparency to stakeholders about the company’s management compensation, potentially impacting its governance and investor relations.
The most recent analyst rating on (HK:1336) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. has announced an adjustment to the composition of its Board Committees, electing Mr. ZHANG Xiaodong to several key committees including the Audit and Related Party Transaction Control Committee, the Nomination and Remuneration Committee, and the Risk Management and Consumer Rights Protection Committee. This strategic adjustment is expected to enhance the company’s governance and oversight capabilities, potentially impacting its operational efficiency and stakeholder confidence positively.
The most recent analyst rating on (HK:1336) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. has announced the composition of its board of directors and the roles within its five key committees. This organizational update is significant for stakeholders as it highlights the company’s governance structure and strategic focus areas, potentially impacting its operational efficiency and market positioning.
The most recent analyst rating on (HK:1336) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. has announced a board meeting scheduled for August 28, 2025, to discuss and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend, which could have implications for the company’s financial strategy and shareholder returns.
The most recent analyst rating on (HK:1336) stock is a Hold with a HK$26.50 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. reported an accumulated gross premium income of RMB137,806.27 million for the period from January to July 2025, marking a 23% year-on-year increase. The company is enhancing its operations through systematic reforms, optimizing its business structure, strengthening distribution channels, and building a service-empowering system to improve efficiency and service quality.
The most recent analyst rating on (HK:1336) stock is a Hold with a HK$26.50 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.